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Abstract 
Objective: Previous studies show that acute tryptophan depletion (ATD), by administration of 
an amino acid drink lacking in tryptophan, can produce clinically significant depressive 
symptoms in subjects who have recovered from major depression. This is more likely in 
people who have had suicidal ideation, recurrent depression, treatment with specific serotonin 
reuptake inhibitors and are female. These risk factors are frequent in older recovered 
depressed people. We aimed to investigate the effects of ATD on mood and cognitive 
function in this group.  Method: Sixteen recovered depressed (RD) subjects and 17 healthy 
comparison subjects, over 60 years of age, participated in a double-blind, placebo controlled, 
crossover study involving administration of a tryptophan depleting and a placebo drink. Mood 
ratings scales were administered at baseline and at 4 and 7 hours post drink on each test day. 
A battery of neuropsychological tests including the modified mini mental state examination 
(3MSE) was administered between 4 and 6hours post drink.  Results: Depletion of plasma 
free tryptophan was 71% at 4 and 7 hours after the active drink. There was no evidence of 
mood change at any time in either group. On 3MSE, analysis of variance showed a significant 
interaction between ATD and group (F=4.18, df=1,31, p=0.050) with the RD group showing a 
decrease during ATD compared with placebo.  Conclusions: There was no evidence of mood 
disturbance during ATD in any subject. This may imply less sensitivity to acute disturbance 
of the 5HT system than in younger recovered patients. 
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Introduction 
Studies using the technique of acute tryptophan depletion by dietary means have been used to 
study the role of the 5HT system in relapse of depression in younger subjects. This technique 
involves administration of a balanced amino acid drink, which is lacking in tryptophan. By 
this means, peripheral tryptophan levels are reduced by 70 to 80% and central serotonin 
synthesis is also reduced (1). No other previous studies have investigated the effects of ATD 
in older people recovered from depression. 
Cognitive impairment is particularly marked in older people with depression and may persist 
following recovery (2). However, the neurobiological basis of these persisting cognitive 
impairments has not been well established. In contrast to previous studies in younger subjects, 
we have reported results suggesting that ATD impairs working memory in older people (3).  
To test the following hypotheses we examined the effects of ATD in a group of older patients 
recovered from depression and a healthy comparison group: 
a) that ATD would transiently but significantly lower mood in older patients recovered from 
depression. 
b) that ATD would induce transient cognitive changes in older patients recovered from 
depression which would be different in extent and/or distribution from those elicited in a 
healthy comparison group.  
Method 
Sixteen older subjects who had recovered from an episode of DSM-IV major depression and 
17 healthy comparison subjects took part. All were over 60 years of age and each was 
screened for physical illness, current depressive illness and dementia. While we did not use a 
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structured interview for depression such as the SCID, diagnoses were made at the time of the 
depression by experienced consultant old age psychiatrists and retrospectively verified before 
study entry by a second independent research psychiatrist (RP) examining hospital case notes 
and by discussion with the patient. The recovered depressed (RD) subjects were symptom free 
for at least 3 months with Montgomery-Åsberg depression rating scale (MADRS) (4) scores 
of less than 8 and Geriatric Depression Scale (GDS) (5) scores less than 12. They were stable 
on medication for the previous 3 months and had not had electro-convulsive therapy within 
the previous year and did not fulfil criteria for bipolar disorder. There was no history of 
significant head injury in either group, all had MMSE (Mini Mental State Examination) (6) 
scores greater than 27. Physical examination was carried out on both patients and the 
comparison group. After a full description of the study, all subjects gave written, informed 
consent. The study was approved by Newcastle and North Tyneside Local Research Ethics 
Committee. 
Procedure and clinical rating 
Participants were tested twice, at least one week apart, in a double blind, placebo controlled, 
random order, cross over design. Following an overnight fast, subjects attended the research 
laboratory when baseline measures were undertaken and the drink administered at 0900 hrs. 
The placebo and depleting drink were of the composition previously described (7) with 
females receiving 80% of this mixture (8). Both were mixed in 300ml of water, flavoured 
with blackcurrant and sweetened with saccharin. Subjects remained at rest in the laboratory 
for the next 7 hours, were accompanied by a researcher and were allowed to read neutral 
material. 
Measures of mood (MADRS, GDS, Hedonic Tone 9, and Profile of Mood Scale (POMS), 10) 
were made and blood samples for free and total tryptophan taken at baseline, then 4 hours, 
7hours (and 27 hours for RD subjects) after each drink.  
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Neuropsychological testing 
Tests were performed on both occasions in the same order, by the same rater. Parallel versions 
were used in balanced order between tests. Computerised tests other than VIGIL were taken 
from the Cambridge Neuropsychological Test Automated Battery (CANTAB, 11). The Rey 
tasks were shortened on the basis of our previous experience of this protocol in order to make 
the testing procedure more manageable for elderly subjects. 
The cognitive test battery was designed to test cognitive domains as follows: 
Global functioning 
Modified Mini Mental State Examination (3MSE) (12) 
Short-term memory span 
Digit span (13) 
Declarative learning and memory 
Rey Auditory Verbal Learning Test (RAVLT) (14) (the recognition trial was omitted) 
Rey Visual Design Learning Test (RVDLT) (14) (the task was modified to omit the usual 
delayed recall and recognition trial). 
Simultaneous and delayed matching to sample (DMTS-CANTAB) 
Attention and executive function 
VIGIL (15).  
Subjects view serially presented random letters over 8 minutes and must respond only to the 
sequence of an ‘A’ followed by a ‘K’. Response latency and errors of omission and 
commission are recorded. 
Digit span backwards (13) 
Controlled oral word association - Verbal fluency (16) 
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Verbal Fluency Performance Test (VFPT) (17) 
Spatial working memory (SWM – CANTAB) 
Tower of London (TOL – CANTAB) 
Biochemical measures 
Blood samples were taken into EDTA tubes and centrifuged to remove plasma. This was 
stored at –20°C. Plasma was also ultra-filtered and stored until assay. Free and total 
tryptophan were measured using high performance liquid chromatography. Intra- and inter-
assay co-efficients of variation for free tryptophan were 3.4% and 4.4% respectively and for 
total tryptophan were 3.3% and 4.4%.  
Analysis 
SPSS for Windows Release 10 (SPSS, Chicago, Illinois) was used. Reaction time data were 
log transformed (base 10) to reduce skewness of distribution and measures of errors or trials 
were square root transformed in order to maintain homogeneity of variance. All variables 
were analysed by repeated measures analysis of variance (R-MANOVA). The dependant 
variable was the biochemical value or neuropsychological test score with treatment (ATD or 
placebo) as a within subject factor and diagnostic group as a between subject variable.  For 
tests with repetitions (RAVLT), levels of difficulty (SWM) or a variable delay (DMTS), this 
was included as a further within subject factor.  In separate analyses, order (order of 
administration of drinks) and gender were entered as between subject factors. Reported p 
values were corrected using the Huynh-Feldt correction factor when the sphericity assumption 
was not met. For clarity, uncorrected degrees of freedom are reported. Data are quoted as 
untransformed means ± standard deviations. The p value used to demonstrate significance was 
set at 0.05 despite multiple neuropsychological tests since the clinical significance of results 
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was to be interpreted in the light of the overall pattern of results of tests tapping similar 
domains.  
Results 
2 male and 1 female recovered depressed subjects were withdrawn during the first visit 
following episodes of vomiting and/or diarrhoea and 1 male and 1 female subjects declined to 
re-attend for the second visit. Data are shown only for those subjects who completed the 
study.  
Demographics and clinical features 
There was no significant difference between groups in age (RD 71.7 ± 7.3 comparison 67.8 ± 
5.1, F=1.77, df=1,31,p=0.087) and NART (RD 108.4 ± 9.0 comparison 112.0 ± 10.9, F=1.02, 
df=1,31, p=0.316). Baseline MADRS was significantly higher in the recovered depressed 
group (RD 3.31 ± 2.91 comparison 1.06 ± 1.89, F=2.65, df=1,31, p=0.012). Sex distribution 
was different but not significantly so (RD: 10 female, 6 male; comparison group: 7 female 
and 10 male; χ2=1.5, df=1, p=0.22). Clinical features of the recovered group are shown in 
Table 1. Eleven patients were on SSRIs and 15 on antidepressants or lithium at the time of 
testing. One patient had experienced psychotic symptoms during an episode of depression. 
Five subjects from the RD group and two from the comparison group were taking 
antihypertensive medication (atenolol, bendrofluazide, ananapril), two subjects from the RD 
group were taking thyroxine, one subject from the RD group suffered from non-insulin 
dependent diabetes and was taking tolbutemide and one subject from the RD group had 
controlled achel fibrillation and was taking warfarin, dedjoxin and fruzamide. Other than this, 
some subjects from either group had suffered from osteoarthritis and were on anti-
inflammatory medications. 
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Biochemical measures 
Measures were unavailable because of failed venous access in 2 recovered subjects. In one 
case the baseline free tryptophan level was several standard deviations higher than the mean 
and was excluded. Baseline free tryptophan levels were 7.31±1.9 on the placebo day and 
7.63±1.7 on the depletion day with no differences between groups. Depletion of free plasma 
tryptophan after ingestion of the active drink at 4 hours was significant (ATD by time; 
F=181.2, df=2,27, p<0.001) with a mean reduction of 72.5% (SD=12.9) at 4 hours and 72.1% 
(SD=17.3) at 7 hours. There was no effect of group (F=0.18, df=1,28, p=0.677) or group by 
ATD interaction (F=0.47, df=1,28, p=0.501). After the placebo drink, free tryptophan rose 
significantly in both groups with a mean increase of 276.7% (SD=127.1) at 4 hours and 
97.3% (SD=62.4) at 7hours. Results for total tryptophan followed a similar pattern. At 27h in 
the RD group free TRP had returned to baseline levels (placebo: 8.27±3.07, depletion: 
7.50±1.94).  
Mood rating measures 
These are summarised in Table 2 and individual responses in the RD group are illustrated in 
Figure 1. No subject experienced a clinically significant increase in symptoms of depression 
during either ATD or placebo on the day of testing. Where there were group effects, the RD 
group scored higher.  
One subject experienced a  notable increase in MADRS on the day following the placebo 
drink. MADRS scores on the placebo arm were : baseline-7, 4 hours-6, 7 hours-7, 27 hours-
15. This change was limited to that day and did not result in sustained relapse. This subject 
was recovered for 2 months and was taking lofepramine.  
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For the RD group, including the day after testing, there was no ATD by time interaction for 
MADRS (F=0.452, df=3,39, p=0.651), GDS (F=1.13, df=3,42, p=0.308) or hedonic tone 
(F=1.02, df=3,42, p=0.394) or any POMS scores (data not shown). 
Neuropsychological tests (Table 3) 
Because of the demanding testing schedule, neuropsychological tests were terminated when 
subjects exhibited signs of fatigue or any distress. Therefore data from some subjects are 
missing from certain tests (see degrees of freedom). This occurred only once in the control 
group (on the Tower of London task) and other missing data are because of termination of 
tasks in the RD group. Where there was a significant main effect of level of a test or delay, 
this was as expected and is not further explored. There were no significant interactions 
between ATD and delay/level of tests.  
Where there was a significant main effect of diagnosis, the RD group performed worse in all 
cases.  
In separate analyses there were no significant effects of gender or interactions between gender 
and ATD or group. 
Global functioning 
Modified mini-mental state examination 
There was a significant effect of diagnosis and interaction between ATD and diagnosis but no 
independent effect of ATD.  3MSE scores were lower in depressed subjects compared with 
controls. In the RD group 3MSE score was lower during ATD (placebo: 95.1±6.5; depletion: 
92.5±6.50) while it was higher in the healthy group (placebo: 97.4±2.48; depletion: 
97.7±2.08).  
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Short-term memory span 
Digit span  
On forward digit span there were significant main effects of diagnosis and ATD but no 
interaction. RD subjects performed worse under both conditions and both groups performed 
worse during ATD (recovered depressed placebo: 7.67±1.29, recovered depressed depletion: 
6.87±1.46; healthy placebo: 9.53±2.21, healthy depletion: 8.71±2.14)  
Declarative learning and memory 
RAVLT 
There was a significant main effect of ATD and a significant interaction between ATD and 
order (F=7.36, df=1,28, p=0.011) on recall of lists 1-5 but no interaction with diagnosis or list 
number. Scores were lower only when subjects received depletion on the second visit 
(Placebo 1st visit: 43.00±12.50, placebo 2nd visit: 45.63±10.38; depletion 1st visit: 44.06±9.84, 
depletion 2nd visit: 34.94±11.66). 
There was a main effect of ATD on recall of list A following the distractor list with recall 
lower during ATD in both groups (RD group; placebo: 6.81±4.45, depletion: 5.31±4.05; 
healthy group; placebo: 8.88±3.18, depletion: 7.47±2.85).  There were no significant effects 
on the distracter list (B), or delayed recall of list A. 
RVDLT 
On list recall, there was a significant effect of ATD (combined group; placebo: 27.93±14.95; 
depletion: 23.23±12.09) but no interaction between ATD and group and none between ATD 
and repetition. There was a significant interaction between ATD and order (F=6.57, df=1,24, 
p=0.01; Placebo 1st visit: 24.67±14.09, placebo 2nd visit: 31.53±14.78; depletion 1st visit: 
22.76±11.61, depletion 2nd visit: 23.85±13.15). 
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Simultaneous and delayed matching to sample 
There were no significant effects of ATD or interactions between ATD and diagnosis. In 
number correct, there was a significant interaction between ATD and order (F=9.69, df=1,29, 
p=0.06; Placebo 1st visit: 30.00±5.61, placebo 2nd visit: 33.25±4.06; depletion 1st visit: 
30.81±4.87, depletion 2nd visit: 30.29±7.53).  
Attention and Executive functioning 
Spatial working memory 
In within search errors, there was an interaction between ATD and order (F=4.96, df=1,29, 
p=0.035; Placebo 1st visit: 1.53±1.70, placebo 2nd visit: 0.81±1.51; depletion 1st visit: 
2.94±3.51, depletion 2nd visit: 1.77±2.22).  
Discussion 
The principle finding of this study was that there was no clinically significant mood reduction 
during ATD in any subject, whether in the patient or the comparison group. ATD induced a 
reduction in 3MSE in the recovered depressed group compared with the healthy group and 
subtle but significant effects on individual cognitive functions in both groups but with no 
differential effect.  
Some previous studies have shown profound reductions in mood during ATD, in patients who 
had recovered from depression (8). A recent meta analysis of such studies suggested that the 
following characteristics predicted the likelihood that ATD would induce significant mood 
reduction in any individual: previous serious suicidal thoughts or behaviours, a history of 
exposure to SSRIs, gender (female), recurrence (more than one episode) (18). Demographics, 
including characteristics likely to predispose to mood reduction during this procedure are 
described in Table 1. Of the risk factors suggested, only one subject in this study did not have 
any, two subjects had one factor, six subjects had two factors, five had three factors and two 
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had all four. Based on this we would have expected significant relapse in at least some 
patients. A recent study in recovered depression suggested that an additional factor mediating 
mood reduction during ATD is a functional polymorphism of the promoter region of the 
serotonin transporter gene (19). Unfortunately we did not determine the genotype of the 
patients in this study. 
Some studies have shown mood reduction on more subtle measures when there has been no 
evidence of reduction on clinical rating scales (e.g. 20) in groups likely to be vulnerable to 
disturbance in the 5HT system. In the current study, there was no effect on mood items in the 
POMS, emphasising the complete lack of mood change seen in this study. A study in 
currently depressed patients demonstrated a delayed effect on mood with effects the day after 
depletion (21). Once again this was not evident in the recovered depressed group who were 
followed up at midday the following day and completed the same mood ratings. 
Protective factors in our patients may have been the relatively long duration of remission in a 
significant percentage of them. In the pooled data set, 46 patients were remitted for less than 
12 months and 24 for greater than 12 months. In our study the figures were 4 and 12 
respectively. However, duration of remission did not emerge as a factor in the analysis of 
Booij (18). It may also be that treatment with lithium reduces the likelihood of relapse (22). 
Three patients in our group were on lithium, possibly reducing the likelihood of ATD induced 
mood change in these individuals. 
Despite the fact that in the analysis of Booij (18) no effect of age was found, age may be an 
important factor. The mean age in that analysis was 39 (range: 21 to 59 years) and is not 
therefore applicable to the older age range described here in our study. The most likely 
explanation for the lack of effect of ATD on mood in our group may be the age of the cohort 
and changes in the 5HT system with aging. Post-mortem studies examining the effects of 
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healthy ageing on the 5HT transporter have been equivocal (see (23) for review). However, 
decreased 5HT2 receptor binding with age has been shown in positron emission tomography 
(PET) studies (24) while a recent PET study suggests a decrease in 5HT1A receptor binding 
with age but only in men (25). In depression, there is little evidence that the effects of aging 
differentially affect response rates to antidepressants with primarily serotonergic compared 
with noradrenergic activity (26).  
It is likely that patients with late onset depression have different neurobiological 
characteristics and that episodes of depression are mediated by vascular factors (27). Four of 
the patients in this study had onset later than 60 years, a number which was too small to 
determine whether there were any differential effects in an early onset group as opposed to a 
late onset group.  
A methodological difference in this study compared with that of Smith et al. (8) is that in the 
current study, in order to replicate the methodology of our study in Alzheimer’s disease, we 
did not use a pre-test low TRP diet. However, subjects did fast for 12 hours prior to the test 
and baseline tryptophan levels were similar to those in other studies, e.g. the same as those in 
Bremner (28).  
Overall, depletion of plasma free tryptophan at 4 and 7 hours was 72%, compared with 
previous studies in recovered depressed subjects (18) in which depletion at 5-7 hours was on 
average 75.3%. However, depletion is maximal at 5 hours and had we measured free TRP 
then we may have found comparable levels. A further methodological issue is the 
composition of the placebo (balanced drink). We used drinks of the same composition as used 
in most studies in recovered depression (18). The placebo drink therefore contained 2.3g/100g 
of L-tryptophan. Using this composition, the increase in free tryptophan was greater than that 
seen in most other studies (277% at 4 hours, 97% at 7hours). A possible explanation for this is 
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that the rate of incorporation of amino acids into protein by the liver is slower in older people. 
However, in a previous study in schizophrenia, in the same centre, the increase in free 
tryptophan in response to the placebo drink was comparable to that seen here (~250%) (29). 
We did not measure tryptophan/LNAA ratio, which would give a better indication of central 
TRP availability. However in the study of Golightly et al (29) the 100g active drink 
selectively reduced the tryptophan/LNAA ratio with no change in the tyrosine/LNAA ratio 
while the placebo drink did not alter either ratio. The lack of change in the tyrosine/LNAA 
ration suggests that there were unlikely to have been significant catecholaminergic effects.  
An interesting finding in this study, in one of the patients recovered from depression, was of 
an increase in MADRS score on the day after the placebo drink. It is notable that this patient 
had a relatively high baseline MADRS score of 8 and had been recovered for less time than 
the other patients (2 months). This may have led him to be susceptible to rapid fluctuations in 
TRP levels. Three previous studies have noted significant change in mood ratings the day 
after ATD. Delgado (21) and Price (30) noted this only following ATD in currently depressed 
subjects. An increase in a 6 item version of the Hamilton Depression Rating Scale of 5 points 
from baseline to the next day following the control drink occurred in the study of Spillmann 
(31) but in this study the control drink consisted of 25% by weight of the active drink and 
produced an average depletion of free TRP of 34%. (Richard – the Smith KA 1997 Lancet 
paper is also a good one – relapse after ATD only). 
There was a small differential effect on 3MSE with no selective effect on other cognitive 
functions in the patient group. This is similar to the pattern found in our previous study of 
patients with Alzheimer’s disease and healthy comparison subjects (3, 32) although the effect 
on the 3MSE in Alzheimer’s disease was greater in that study and there was only a trend 
towards a study group by ATD interaction in that study. It may be that the 3MSE, because of 
its broader range, is able to show an effect where more complex tasks tapping specific 
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functions are not. The finding of a differential effect on 3MSE, but no effect on mood is 
similar to the finding of Moore et al. (33) that despite no effect on mood, there were 
significant effects on sleep architecture in recovered depressed subjects. Moore et al. 
hypothesised that this is secondary to an impairment in the 5HT system in the recovered 
depressed which does not, however, manifest itself in mood changes.  
Over both arms of the study, the RD group performed less well than the comparison group on 
several of the tests including delayed matching to sample and spatial working memory. This 
finding is not surprising since significant residual cognitive deficit has been consistently 
reported in recovered older depressed people (2).  
Detailed neuropsychological testing showed specific effects of ATD on a number of 
functions. In particular, there was a significant effect of ATD on words recalled in the 
RAVLT, pattern recall in the RVDLT, and score on the digit span forward. In all cases, 
performance was poorer when subjects were undergoing ATD. All these results, particularly 
in the absence of an interaction with list number in the Rey tasks suggest an effect on working 
memory rather than memory consolidation. This finding is in contrast to studies in younger 
subjects which have found no effect on working memory or other functions observed by 
dorsolateral prefrontal cortex, but which have found an effect on memory consolidation (34). 
Overall, the results add some evidence to our previous findings that in older people ATD 
impairs aspects of working memory (3). We believe that the most likely explanation for this 
phenomenon is that tasks of working memory are more sensitive with increasing age. It has 
been shown that performance on working memory tasks declines from the age of 
approximately 30 (35). This would mean that these tests are more sensitive to subtle 
disruptions in older groups.  
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This is the first study of acute tryptophan depletion in older recovered depressed subjects. The 
finding of no mood reduction in any of the subjects may imply that this group is, in general, 
less vulnerable to acute perturbation of the 5HT system than younger recovered depressed. 
However, as in our previous study of SDAT compared with the comparison group, there was 
a reduction in 3MSE in recovered depression but not the healthy group, suggesting that this 
may be a marker of serotonergic vulnerability.  
 17
References 
1. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, Blier 
P, Diksic M: Differences between males and females in rates of serotonin synthesis in 
human brain. Proc Natl Acad Sci U S A 1997; 94(10):5308-5313 
2. Beats BC, Sahakian BJ, Levy R: Cognitive performance in tests sensitive to frontal 
lobe dysfunction in the elderly depressed. Psychol Med 1996; 26:591-603 
3. Porter RJ, Lunn BS, O'Brien J: Effects of acute tryptophan depletion on cognitive 
function in Alzheimer's disease and in the healthy elderly. Psychol Med 2003; 33:41-
49 
4. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to 
change. Br J Psychiatry 1979; 134:382-389 
5. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: 
Development and validation of a geriatric depression screening scale: a preliminary 
report. J Psychiatr Res 1982; 17(1):37-49 
6. Folstein M, Folstein S, McHugh P: "Mini mental state" a practical method for grading 
the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198 
7. Young SN, Smith SE, Pihl RO, Ervin FR: Tryptophan depletion causes a rapid 
lowering of mood in normal males. Psychopharmacology (Berl) 1985; 87(2):173-177 
8. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of 
tryptophan. Lancet 1997; 349(9056):915-919 
9. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P: A scale for 
the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 
1995; 167(1):99-103 
10. McNair DM, Lorr M, Droppleman LF: Edits manual for the profile of mood states. 
San Diego, Educational and Industrial Testing Service, 1992 
11. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P: Cambridge 
Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a 
large sample of normal elderly volunteers. Dementia 1994; 5(5):266-281 
12. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin 
Psychiatry 1987; 48(8):314-318 
13. Wechsler D: Wechsler Adult  Intelligence Scale - Revised. New York, The 
Psychological Corporation, 1981 
14. Rey A: L'Examen Clinique en Psychologie. Paris, Press Universitaire de France, 1964 
15. Cegalis J, Bowlin J: Vigil: software for the assessment of attention. Nashua, NH, 
Forthought, 1991 
16. Benton AL, Hamsher K: Multilingual Aphasia Examination. Iowa City, University of 
Iowa, 1976 
17. Bryan J, Luszcz MA, Crawford JR: Verbal knowledge and speed of information 
processing as mediators of age differences in verbal fluency performance among older 
adults. Psychol Aging 1997; 12(3):473-478 
 18
18. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M, Gillin C, 
Leyton M, Moore P, Smith KA, Van der Kloot WA: Predictors of mood response to 
acute tryptophan depletion: A reanalysis. Neuropsychopharmacology 2002; 27(5):852-
861 
19. Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J, Delgado PL: 
Association between a serotonin transporter promoter region polymorphism and mood 
response during tryptophan depletion. Mol Psychiatry 2002; 7(2):213-216 
20. Sobczak S, Honig A, Nicholson N, Riedel W: Effects of acute tryptophan depletion on 
mood and cortisol release in first-degree relatives of type I and type II bipolar patients 
and healthy matched controls. Neuropsychopharmacology 2002; 27(5):834-842 
21. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, 
Charney DS: Serotonin and the neurobiology of depression. Effects of tryptophan 
depletion in drug-free depressed patients. Arch Gen Psychiatry 1994; 51(11):865-874 
22. Johnson L, El-Khoury A, Aberg-Wistedt A, Stain-Malmgren R, Mathe AA: 
Tryptophan depletion in lithium-stabilized patients with affective disorder. Int J 
Neuropsychopharmacol 2001; 4(4):329-336 
23. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, 
Reynolds CF: Serotonin in aging, late-life depression, and Alzheimer's disease: the 
emerging role of functional imaging. Neuropsychopharmacology 1998; 18(6):407-430 
24. Meltzer CC, Smith G, Price JC, Reynolds CF, 3rd, Mathis CA, Greer P, Lopresti B, 
Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST: 
Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: 
persistence of effect after partial volume correction. Brain Res 1998; 813(1):167-171 
25. Meltzer CC, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, Villemagne VL, 
Holt D, Mason NS, Houck PR, Reynolds IIICF, DeKosky ST: Gender-specific aging 
effects on the serotonin 1A receptor. Brain Res 2001; 895(1-2):9-17 
26. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, Houck PR, 
Bensasi S, Mazumdar S, Reynolds CF, 3rd: A double-blind randomized comparison of 
nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J 
Clin Psychiatry 1999; 60(Suppl 20):16-20 
27. Thomas AJ, O'Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH: 
Ischemic basis for deep white matter hyperintensities in major depression: A 
neuropathological study. Arch Gen Psychiatry 2002; 59(9):785-792 
28. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, 
Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS: 
Positron emission tomography measurement of cerebral metabolic correlates of 
tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997; 
54(4):364-374 
29. Golightly KL, Lloyd JA, Hobson JE, Gallagher P, Mercer G, Young AH: Acute 
tryptophan depletion in schizophrenia. Psychol Med 2001; 31(1):75-84 
30. Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR: The neurobiology of 
tryptophan depletion in depression: effects of intravenous tryptophan infusion. Biol 
Psychiatry 1998; 43(5):339-347 
31. Spillmann MK, Van der Does AJW, Rankin MA, Vuolo RD, Alpert JE, Nierenberg 
AA, Rosenbaum JF, Hayden D, Schoenfeld D, Fava M: Tryptophan depletion in 
 19
SSRI-recovered depressed outpatients. Psychopharmacology (Berl) 2001; 155(2):123-
127 
32. Porter RJ, Lunn BS, Walker LL, Gray JM, Ballard CG, O'Brien JT: Cognitive deficit 
induced by acute tryptophan depletion in patients with Alzheimer's disease. Am J 
Psychiatry 2000; 157(4):638-640 
33. Moore P, Gillin C, Bhatti T, DeModena A, Seifritz E, Clark C, Stahl S, Rapaport M, 
Kelsoe J: Rapid tryptophan depletion, sleep electroencephalogram, and mood in men 
with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 1998; 
55(6):534-539 
34. Riedel WJ: Cognitive changes after acute tryptophan depletion: what can they tell us? 
Psychol Med 2004; 34:3-8 
35. De Luca CR, Wood SJ, Anderson V, Buchanan JA, Proffitt TM, Mahony K, Pantelis 
C: Normative data from the CANTAB. I: development of executive function over the 
lifespan. J Clin Exp Neuropsychol 2003; 25(2):242-254 
 
 20
Table 1. Clinical characteristics of subjects recovered from depression 
Age Age of 
onset 
Sex Suicidal 
acts 
No of 
previous 
episodes 
Time since 
recovery 
(months) 
Duratio
n last 
episode 
Current 
Psychotropic 
Medications 
Exposure 
to SSRIs 
81 78 M  0 6 24 fluoxetine  Yes 
60 28 F  1 40 12 fluoxetine  Yes 
76 30 F  2 24 12 fluoxetine  Yes 
60 45 M Yes 6 12 24 fluoxetine, 
olanzapine,  
Yes 
72 55 F Yes 1 21 12 fluoxetine, 
sodium valproate 
Yes 
73 19 F  4 12 4 fluoxetine, 
thioridazine  
Yes 
71 62 F  0 116 1 paroxetine  Yes 
85 65 M  1 8 2 paroxetine  Yes 
74 43 M  1 5 3 paroxetine  Yes 
77 71 M  2 54 48 paroxetine, 
lithium 
Yes 
64 62 M  0 3  24 lofepramine  No 
80 54 F yes 3 36 13 lofepramine, 
lithium 
Yes 
65 30 F  2 156 12 maprotiline No 
74 70 F  0 34 12 dothiepin  No 
67 31 F  5 52 3 lithium  Yes 
68 28 F  1 30 12 none  No 
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Table 2. Effects of ATD on mood and side effect measures – repeated measures analysis 
of variance 
Measure ATD Group ATD x group ATD x time 
 F p F p F p F p df 
MADRS 0.89 0.352 5.30 0.028 2.31 0.139 1.60 0.209 2,62 
GDS 0.48 0.495 6.74 0.014 0.01 0.920 0.27 0.765 2,62 
Hedonic tone 0.25 0.621 0.25 0.619 2.84 0.102 0.29 0.603 2,62 
POMS          
Total mood 
score 
0.142 0.712 7.76 0.014 0.22 0.712 0.38 0.960 2,30 
Tense anxious 2.56 0.122 3.86 0.061 0.75 0.395 0.11 0.851 2,50 
Depressed 
dejected 
0.007 0.936 7.63 0.010 0.084 0.774 0.586 0.546 2,54 
Anger hostility 0.410 0.528 4.40 0.046 0.029 0.865 0.716 0.443 2,52 
Vigour 0.158 0.695 1.42 0.244 <0.001 0.998 2.30 0.770 2,54 
Fatigue 0.086 0.773 0.497 0.488 0.029 0.866 0.014 0.981 2,46 
Confused 
bewildered 
3.56 0.071 4.04 0.055 2.81 0.071 0.927 0.402 2,50 
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Table 3. Effects of ATD on neuropsychological measures – repeated measures analysis 
of variance 
Test Variable Main effect acute 
tryptophan depletiona 
Main effect study groupb Interaction acute 
tryptophan depletion 
and study group 
  F df p F df p F df p 
3MSE Total score 2.66 1,31 0.113 6.30 1,31 0.018 4.18 1,31 0.050 
Digit 
span-fwd 
Total score 7.99 1,31 0.008 9.90 1,31 0.004 0.02 1,31 0.968 
RAVLT List A recall 12.42 1,31 0.003 3.63 1,31 0.066 1.39 1,31 0.248 
 List B recall 0.106 1,31 0.747 2.76 1,31 0.107 2.03 1,31 0.165 
 List A recall 
(after 
distractor) 
8.14 1,31 0.008 3.26 1,31 0.081 0.007 1,31 0.932 
 List A 
delayed 
recall 
3.616 1,30 0.067 1.89 1,30 0.179 0.014 1,30 0.906 
RVDLT List recall 4.62 1,26 0.041 2.78 1,26 0.108 1.59 1,26 0.218 
DMTS Correct score 0.06 1,31 0.811 6.29 1,31 0.018 0.14 1,31 0.713 
 Correct 
latency 
0.022 1,31 0.882 5.51 1,31 0.026 2.00 1,31 0.168 
Vigil Delay 1.69 1,27 0.205 0.62 1,27 0.440 4.16 1,27 0.052 
 Omissions 0.147 1,27 0.704 0.104 1,27 0.749 3.78 1,27 0.062 
 Commissions 3.74 1,27 0.064 0.08 1,27 0.775 0.14 1,27 0.716 
Digit 
span-bwd 
Total score 0.001 1,31 0.985 0.04 1,31 0.841 0.09 1,31 0.766 
FAS Total score 1.01 1,31 0.322 1.41 1,31 0.245 0.18 1,31 0.678 
VFPT Total score 0.04 1,31 0.951 4.05 1,31 0.053 0.783 1,31 0.384 
SWM Strategy 
count (set 
length 6-8) 
1.62 1,31 0.213 4.12 1,31 0.051 0.133 1,31 0.717 
 Within 
search errors 
3.88 1,31 0.058 5.03 1,31 0.032 0.712 1,31 0.405 
 Between 
search errors 
0.850 1,31 0.457 14.79 1,31 0.001 <0.001 1,31 0.999 
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Test Variable Main effect acute 
tryptophan depletiona 
Main effect study groupb Interaction acute 
tryptophan depletion 
and study group 
  F df p F df p F df p 
Tower of 
London 
No of excess 
moves 
0.653 1,26 0.426 0.753 1,26 0.393 0.257 1,26 0.616 
 Proportion of 
perfect 
solutions 
3.24 1,26 0.083 2.32 1,26 0.139 0.293 1,26 0.593 
a acute tryptophan depletion induced by a tryptophan-deficient amino acid drink compared 
with placebo (a drink containing a balanced mixture of amino acids) 
b subjects with recovered depression compared with healthy comparison subjects 
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Figure 1: Individual scores on MADRS scale before, 7hours and 27 hours after tryptophan 
free (depleting) or nutritionally balanced (placebo) amino acid mixture 
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